{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:43:50Z","timestamp":1761871430129,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.clml.2020.04.006","type":"journal-article","created":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T12:03:51Z","timestamp":1588939431000},"page":"e590-e596","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["The Use of 20% Subcutaneous Immunoglobulin Replacement Therapy in Patients With B Cell Non-Hodgkin Lymphoma With Humoral Immune Dysfunction After Treatment With Rituximab"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9691-7590","authenticated-orcid":false,"given":"S. Shahzad","family":"Mustafa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saad","family":"Jamshed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1980-5573","authenticated-orcid":false,"given":"Karthik","family":"Vadamalai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1691-4232","authenticated-orcid":false,"given":"Allison","family":"Ramsey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.04.006_bib1","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1111\/trf.14841","article-title":"Systematic review of rituximab for autoimmune diseases: A potential alternative to intravenous immune globulin","volume":"58","author":"MacIsaac","year":"2018","journal-title":"Transfusion"},{"key":"10.1016\/j.clml.2020.04.006_bib2","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1200\/JCO.1999.17.6.1851","article-title":"Single-agent monoclonal antibody efficacy in bulky non-Hodgkin\u2019s lymphoma: results of a phase II trial of rituximab","volume":"17","author":"Davis","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.04.006_bib3","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.04.006_bib4","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13075-017-1306-0","article-title":"B\u00a0cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients","volume":"19","author":"Thiel","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.clml.2020.04.006_bib5","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3109\/08916934.2014.914174","article-title":"Reconstitution of the peripheral B lymphocyte compartment in patients with ANCA-associated vasculitides treated with rituximab for relapsing or refractory disease","volume":"47","author":"Venhoff","year":"2014","journal-title":"Autoimmunity"},{"key":"10.1016\/j.clml.2020.04.006_bib6","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.ijid.2010.03.025","article-title":"Does rituximab increase the incidence of infectious complications? A narrative review","volume":"15","author":"Kelesidis","year":"2011","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.clml.2020.04.006_bib7","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1093\/annonc\/mdl141","article-title":"High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication","volume":"17","author":"Cabanillas","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2020.04.006_bib8","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2014.11.009","article-title":"Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease","volume":"57","author":"Roberts","year":"2015","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.clml.2020.04.006_bib9","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1080\/08830185.2017.1346092","article-title":"Risk factors predisposing to the development of hypogammaglobulinemia and infections post-rituximab","volume":"36","author":"Christou","year":"2017","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.clml.2020.04.006_bib10","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections","volume":"13","author":"Casulo","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2020.04.006_bib11","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/qjmed\/hcu094","article-title":"Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes","volume":"107","author":"Makatsori","year":"2014","journal-title":"QJM"},{"key":"10.1016\/j.clml.2020.04.006_bib12","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.clim.2016.04.001","article-title":"Intravenous versus subcutaneous immunoglobulin replacement in secondary hypogammaglobulinemia","volume":"166-167","author":"Spadaro","year":"2016","journal-title":"Clin Immunol"},{"key":"10.1016\/j.clml.2020.04.006_bib13","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3324\/haematol.2013.101261","article-title":"Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients","volume":"99","author":"Compagno","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.04.006_bib14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2010.08076.x","article-title":"The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases","volume":"149","author":"Cooper","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.04.006_bib15","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jaip.2014.06.003","article-title":"Rituximab and immune deficiency: case series and review of the literature","volume":"2","author":"Kaplan","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.clml.2020.04.006_bib16","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/08923973.2017.1392562","article-title":"Infectious diseases and immunological markers associated with patients with non-Hodgkin lymphoma treated with rituximab","volume":"40","author":"de Souza","year":"2018","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"10.1016\/j.clml.2020.04.006_bib17","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.jaci.2015.04.049","article-title":"Practice parameter for the diagnosis and management of primary immunodeficiency","volume":"136","author":"Bonilla","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.clml.2020.04.006_bib18","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jaci.2017.12.980","article-title":"Update: vaccines in primary immunodeficiency","volume":"141","author":"Bonilla","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.clml.2020.04.006_bib19","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2012.07.002","article-title":"Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology","volume":"130","author":"Orange","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.clml.2020.04.006_bib20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3389\/fimmu.2019.00033","article-title":"The expanding field of secondary antibody deficiency: causes, diagnosis, and management","volume":"10","author":"Patel","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.clml.2020.04.006_bib21","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1002\/art.27555","article-title":"Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry","volume":"62","author":"Gottenberg","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clml.2020.04.006_bib22","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/ejh.13223","article-title":"Current clinical practice and challenges in the management of secondary immunodeficiency in hematological malignancies","volume":"102","author":"Na","year":"2019","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2020.04.006_bib23","doi-asserted-by":"crossref","first-page":"e100324","DOI":"10.1371\/journal.pone.0100324","article-title":"Primary vs. secondary antibody deficiency: clinical features and infection outcomes of immunoglobulin replacement","volume":"9","author":"Duraisingham","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2020.04.006_bib24","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jaci.2011.08.008","article-title":"Effect of rituximab on human in\u00a0vivo antibody immune responses","volume":"128","author":"Pescovitz","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.clml.2020.04.006_bib25","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/art.25033","article-title":"Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab","volume":"62","author":"van Assen","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clml.2020.04.006_bib26","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/art.25034","article-title":"Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial","volume":"62","author":"Bingham","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clml.2020.04.006_bib27","doi-asserted-by":"crossref","first-page":"5464","DOI":"10.1016\/j.vaccine.2012.06.073","volume":"30","author":"Thierry-Carstensen","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.clml.2020.04.006_bib28","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jaip.2015.07.025","article-title":"International consensus document (ICON): common variable immunodeficiency disorders","volume":"4","author":"Bonilla","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.clml.2020.04.006_bib29","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jaip.2019.07.032","article-title":"Rituximab unveils hypogammaglobulinemia and immunodeficiency in children with autoimmune cytopenia","volume":"8","author":"Ottaviano","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.clml.2020.04.006_bib30","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s10875-006-9021-7","article-title":"Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases","volume":"26","author":"Ochs","year":"2006","journal-title":"J\u00a0Clin Immunol"},{"key":"10.1016\/j.clml.2020.04.006_bib31","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2165\/11587030-000000000-00000","article-title":"Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency","volume":"50","author":"Wasserman","year":"2011","journal-title":"Clin Pharmacokinet"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020301841?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020301841?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:34:20Z","timestamp":1761870860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020301841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S2152265020301841"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.04.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Use of 20% Subcutaneous Immunoglobulin Replacement Therapy in Patients With B Cell Non-Hodgkin Lymphoma With Humoral Immune Dysfunction After Treatment With Rituximab","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}